author-photo

Eva Lumbreras

University of Salamanca

55

Papers

590

Citations

Citation Trend

Filter By

Papers (37) Sort By

Journal Conference Others

Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.

2021 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients

2020 Pharmacogenomics Journal
Show All
- Source
- Cite
- Save
Citations (2)
Machine learning applied to gene expression analysis of T-lymphocytes in patients with cGVHD.

2020 Bone Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (2)
Comprehensive Custom NGS Panel Validation for the Improvement of the Stratification of B-Acute Lymphoblastic Leukemia Patients.

2020 Journal of Personalized Medicine
Show All
- Source
- Cite
- Save
Citations (1)
Sequential Study By RNA-Seq Shows a Reduction in Inflammation and a Cell Cycle Activation in T-Lymphocytes from Myelodysplastic Syndrome with Del(5q) after Lenalidomide Treatment in Patients Included in the Sintra-REV Clinical Trial

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Integrated Transcriptomic and Proteomic Analyses of Inflammasome in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS: PF533

2019
Show All
- Source
- Cite
- Save
Citations (0)
Transcriptomic rationale for synthetic lethality‐targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia

2018 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (3)
Genomic Instability and a Preferential Involvement of Ras Pathway in the Myelodysplastic Syndromes Evolution to Secondary Acute Myeloid Leukemia

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) - Preliminary Blinded Analysis of the European Sintra-REV Trial

2018 Blood
Show All
- Source
- Cite
- Save
Citations (2)